Home » Glaxo Buys UCB’s Emerging Market Activities
Glaxo Buys UCB’s Emerging Market Activities
The world’s second-largest pharmaceutical group GlaxoSmithKline Plc has agreed to buy Belgian peer UCB’s operations in a number of emerging markets for 515 million euros (484 million pounds).
International Herald Tribune
International Herald Tribune
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May